FGF2 and neoplasm: Although LeTx treatment does decrease the release of a number of angio-proliferative factors, including basic fibroblast growth factor (bFGF), IL-8, and VEGF from tumor cells [11] it appears that the primary effects of LeTx are mediated by a non-tumor compartment, likely endothelial cells [11], [12], [13].